Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

ShangPharma Partners with Scripps Research to Form $15 Million US Accelerator

publication date: Jun 9, 2017
ShangPharma Innovation, the US-based biopharma incubator arm of China CRO ShangPharma, will collaborate with The Scripps Research Institute (TSRI) and its drug discovery affiliate, California Institute for Biomedical Research (Calibr), to accelerate the development of innovative drug candidates. ShangPharma will contribute $15 million in funding and in-kind services over three years. TSRI/Calibr will suggest promising drug candidates. TSRI/Calibr will own rights to the projects, while ShangPharma will receive a portion of any proceeds they may produce. TSRI and Calibr are both located in La Jolla, California. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China